Evolus reports Q4 EPS 0c, consensus 4c

Reports Q4 revevnuee $90.3M, consensus $89.58M. “In 2025 we generated nearly $300 million in total net revenue delivering our sixth consecutive year of double-digit growth,” said David Moatazedi, President and Chief Executive Officer of Evolus (EOLS). “Our performance beauty positioning supported by clinically differentiated products has enabled us to continue to outpace the market while strengthening U.S. and International share for Jeuveau and successfully expanding our U.S. injectable portfolio with the launch of Evolysse. The consistency of our relative outperformance reflects the durability of our commercial model and the growing relevance of our portfolio to today’s aesthetic consumer.”